The aim of the MAST trial is to define best practice in the use of anti-epileptic drugs for patients following a traumatic brain injury.

The MAST trial is broken into two arms: MAST-PROPHYLAXIS and MAST-DURATION.

The MAST-PROPHYLAXIS trial has been designed to assess the clinical effectiveness of a short course of phenytoin or levetiracetam, used as seizure prophylaxis.

The MAST-DURATION trial has been designed to determine the clinical effectiveness of a short course versus a longer course of AEDs in the prevention of further seizures. The two closely related clinical trials will be conducted, in parallel but independent of each other.